<DOC>
	<DOC>NCT02698579</DOC>
	<brief_summary>This is a multi-center, long-term safety and efficacy follow-up study for subjects with cerebral adrenoleukodystrophy (CALD) who have received Lenti-D Drug Product in Study ALD-102. After completing Study ALD-102 (approximately 2 years), eligible subjects will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in this study.</brief_summary>
	<brief_title>Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product</brief_title>
	<detailed_description />
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<criteria>Provision of written informed consent for this study by the subject or subject's parent(s)/ legal guardian(s) and written informed assent by subject, if applicable Have received LentiD Drug Product in Study ALD102 Able to comply with study requirements. Met the VCN discontinuation criterion on Study ALD102, as follows: the subject has undetectable VCN (&lt;0.0003 copies per cell) in peripheral blood cells for 2 consecutive measurements at least 1 month apart and at least 12 months after drug product infusion.</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adrenoleukodystrophy</keyword>
	<keyword>X-linked Adrenoleukodystrophy</keyword>
	<keyword>Hematopoietic Stem Cells</keyword>
</DOC>